SYNERGISTIC ACTIONS OF INTRAVENOUS ANESTHETICS

NIH RePORTER · NIH · R01 · $11,619 · view on reporter.nih.gov ↗

Abstract

Abstract Many clinically-used sedative and anesthetic agents act by modulating the function of the γ-aminobutyric acid type A (GABAA) receptor. The GABAA receptor is the major inhibitory transmittergated ion channel in the brain. Inhibition mediated by GABAA receptors sets the overall activity of the brain, while in individual cells it determines the propensity of a cell to fire an action potential in response to a given excitatory input. The GABAA receptor is also a target for numerous endogenous compounds including neuroactive steroids, that can reduce the dosage requirement for intravenous anesthetics. The overall goal of this project is to investigate how various endogenous compounds and clinically used drugs modify the functioning of the GABAA receptor and initiate the onset and offset of anesthesia. Specifically, we will: i) examine the interactions between binding sites for various classes of GABAergic anesthetics; ii) test the hypothesis that modulation of tonic activity from synaptic-type GABAA receptors contributes to the actions of anesthetics; iii) determine the effects of anesthetic drug combinations on the function of native GABAA receptors; iv) test the hypothesis that endogenous steroids act as co-agonists enhancing the behavioral effects of clinically used GABAergic anesthetic drugs; and v) test the usefulness of competitive steroid-antagonists in promoting emergence from anesthesia.

Key facts

NIH application ID
10145994
Project number
3R01GM108580-06S1
Recipient
WASHINGTON UNIVERSITY
Principal Investigator
GUSTAV AKK
Activity code
R01
Funding institute
NIH
Fiscal year
2020
Award amount
$11,619
Award type
3
Project period
2014-08-01 → 2022-11-30